{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T19:46:35Z","timestamp":1791229595171,"version":"4.1.0"},"reference-count":61,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2020,7,25]],"date-time":"2020-07-25T00:00:00Z","timestamp":1595635200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004622","name":"KWF Kankerbestrijding","doi-asserted-by":"publisher","award":["UVA grant number 10595"],"award-info":[{"award-number":["UVA grant number 10595"]}],"id":[{"id":"10.13039\/501100004622","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cells"],"abstract":"<jats:p>Cytoreductive surgery (CRS) followed by hyperthermic intraperitoneal chemotherapy (HIPEC) is a treatment with curative intent for peritoneal metastasis of colorectal cancer (CRC). Currently, there is no standardized HIPEC protocol: choice of drug, perfusate temperature, and duration of treatment vary per institute. We investigated the temperature-dependent effectiveness of drugs often used in HIPEC. Methods: The effect of temperature on drug uptake, DNA damage, apoptosis, cell cycle distribution, and cell growth were assessed using the temperature-dependent IC50 and Thermal Enhancement Ratio (TER) values of the chemotherapeutic drugs cisplatin, oxaliplatin, carboplatin, mitomycin-C (MMC), and 5-fluorouracil (5-FU) on 2D and 3D CRC cell cultures at clinically relevant hyperthermic conditions (38\u201343 \u00b0C\/60 min). Results: Hyperthermia alone decreased cell viability and clonogenicity of all cell lines. Treatment with platinum-based drugs and MMC resulted in G2-arrest. Platinum-based drugs display a temperature-dependent synergy with heat, with increased drug uptake, DNA damage, and apoptosis at elevated temperatures. Apoptotic levels increased after treatment with MMC or 5-FU, without a synergy with heat. Conclusion: Our in vitro results demonstrate that a 60-min exposure of platinum-based drugs and MMC are effective in treating 2D and 3D CRC cell cultures, where platinum-based drugs require hyperthermia (&gt;41 \u00b0C) to augment effectivity, suggesting that they are, in principle, suitable for HIPEC.<\/jats:p>","DOI":"10.3390\/cells9081775","type":"journal-article","created":{"date-parts":[[2020,7,27]],"date-time":"2020-07-27T04:39:50Z","timestamp":1595824790000},"page":"1775","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":57,"title":["The Temperature-Dependent Effectiveness of Platinum-Based Drugs Mitomycin-C and 5-FU during Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Colorectal Cancer Cell Lines"],"prefix":"10.3390","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9692-7115","authenticated-orcid":false,"given":"Roxan F.C.P.A.","family":"Helderman","sequence":"first","affiliation":[{"name":"Laboratory for Experimental Oncology and Radiobiology (LEXOR), Center for Experimental and Molecular Medicine (CEMM), Amsterdam University Medical Centers (UMC), University of Amsterdam, Cancer Center Amsterdam, P.O. Box 22700, 1100 DE Amsterdam, The Netherlands"},{"name":"Department of Radiation Oncology, Amsterdam UMC, University of Amsterdam, P.O. Box 22700, 1100 DE Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daan R.","family":"L\u00f6ke","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Amsterdam UMC, University of Amsterdam, P.O. Box 22700, 1100 DE Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0648-0642","authenticated-orcid":false,"given":"Jan","family":"Verhoeff","sequence":"additional","affiliation":[{"name":"Department of Molecular Cell Biology &amp; Immunology, Amsterdam Infection &amp; Immunity Institute and Cancer Center Amsterdam, Amsterdam UMC, P.O. Box 7057, 1007 MB Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans M.","family":"Rodermond","sequence":"additional","affiliation":[{"name":"Laboratory for Experimental Oncology and Radiobiology (LEXOR), Center for Experimental and Molecular Medicine (CEMM), Amsterdam University Medical Centers (UMC), University of Amsterdam, Cancer Center Amsterdam, P.O. Box 22700, 1100 DE Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregor G.W.","family":"van Bochove","sequence":"additional","affiliation":[{"name":"Laboratory for Experimental Oncology and Radiobiology (LEXOR), Center for Experimental and Molecular Medicine (CEMM), Amsterdam University Medical Centers (UMC), University of Amsterdam, Cancer Center Amsterdam, P.O. Box 22700, 1100 DE Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Menno","family":"Boon","sequence":"additional","affiliation":[{"name":"Laboratory for Experimental Oncology and Radiobiology (LEXOR), Center for Experimental and Molecular Medicine (CEMM), Amsterdam University Medical Centers (UMC), University of Amsterdam, Cancer Center Amsterdam, P.O. Box 22700, 1100 DE Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanne","family":"van Kesteren","sequence":"additional","affiliation":[{"name":"Laboratory for Experimental Oncology and Radiobiology (LEXOR), Center for Experimental and Molecular Medicine (CEMM), Amsterdam University Medical Centers (UMC), University of Amsterdam, Cancer Center Amsterdam, P.O. Box 22700, 1100 DE Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan J.","family":"Garcia Vallejo","sequence":"additional","affiliation":[{"name":"Department of Molecular Cell Biology &amp; Immunology, Amsterdam Infection &amp; Immunity Institute and Cancer Center Amsterdam, Amsterdam UMC, P.O. Box 7057, 1007 MB Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H. Petra","family":"Kok","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Amsterdam UMC, University of Amsterdam, P.O. Box 22700, 1100 DE Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3146-3310","authenticated-orcid":false,"given":"Pieter J.","family":"Tanis","sequence":"additional","affiliation":[{"name":"Department for Surgery, Amsterdam UMC, University of Amsterdam, Cancer Center Amsterdam, P.O. Box 22700, 1100 DE Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5522-9406","authenticated-orcid":false,"given":"Nicolaas A.P.","family":"Franken","sequence":"additional","affiliation":[{"name":"Laboratory for Experimental Oncology and Radiobiology (LEXOR), Center for Experimental and Molecular Medicine (CEMM), Amsterdam University Medical Centers (UMC), University of Amsterdam, Cancer Center Amsterdam, P.O. Box 22700, 1100 DE Amsterdam, The Netherlands"},{"name":"Department of Radiation Oncology, Amsterdam UMC, University of Amsterdam, P.O. Box 22700, 1100 DE Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7474-0533","authenticated-orcid":false,"given":"Johannes","family":"Crezee","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Amsterdam UMC, University of Amsterdam, P.O. Box 22700, 1100 DE Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arlene L.","family":"Oei","sequence":"additional","affiliation":[{"name":"Laboratory for Experimental Oncology and Radiobiology (LEXOR), Center for Experimental and Molecular Medicine (CEMM), Amsterdam University Medical Centers (UMC), University of Amsterdam, Cancer Center Amsterdam, P.O. Box 22700, 1100 DE Amsterdam, The Netherlands"},{"name":"Department of Radiation Oncology, Amsterdam UMC, University of Amsterdam, P.O. Box 22700, 1100 DE Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2020,7,25]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"394","DOI":"10.3322\/caac.21492","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1016\/S0140-6736(13)61649-9","article-title":"Colorectal cancer","volume":"383","author":"Brenner","year":"2014","journal-title":"Lancet"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1038\/nrc1886","article-title":"Metastasis: A question of life or death","volume":"6","author":"Mehlen","year":"2006","journal-title":"Nat. Rev. Cancer"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1046\/j.1365-2168.2002.02274.x","article-title":"Peritoneal carcinomatosis from colorectal cancer","volume":"89","author":"Jayne","year":"2002","journal-title":"Br. J. Surg."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"782890","DOI":"10.1155\/2014\/782890","article-title":"Colorectal cancer: Prevention and management of metastatic disease","volume":"2014","author":"Sugarbaker","year":"2014","journal-title":"Biomed. Res. Int."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.ijsu.2015.08.078","article-title":"Impacts of low peritoneal cancer index on the survival outcomes of patient with peritoneal carcinomatosis of colorectal origin","volume":"23","author":"Huang","year":"2015","journal-title":"Int. J. Surg."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Pelz, J.O., Chua, T.C., Esquivel, J., Stojadinovic, A., Doerfer, J., Morris, D.L., Maeder, U., Germer, C.T., and Kerscher, A.G. (2010). Evaluation of best supportive care and systemic chemotherapy as treatment stratified according to the retrospective peritoneal surface disease severity score (PSDSS) for peritoneal carcinomatosis of colorectal origin. BMC Cancer, 10.","DOI":"10.1186\/1471-2407-10-689"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"5608","DOI":"10.1002\/cncr.25356","article-title":"Toward curative treatment of peritoneal carcinomatosis from nonovarian origin by cytoreductive surgery combined with perioperative intraperitoneal chemotherapy: A multi-institutional study of 1290 patients","volume":"116","author":"Glehen","year":"2010","journal-title":"Cancer"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/S1470-2045(04)01425-1","article-title":"Peritoneal carcinomatosis from digestive tract cancer: New management by cytoreductive surgery and intraperitoneal chemohyperthermia","volume":"5","author":"Glehen","year":"2004","journal-title":"Lancet Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"433","DOI":"10.2307\/3575883","article-title":"Interaction of thermotolerance and thermosensitization induced in CHO cells by combined hyperthermic treatments at 40 and 43 degrees C","volume":"91","author":"Jung","year":"1982","journal-title":"Radiat. Res."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/S1040-8428(01)00179-2","article-title":"The cellular and molecular basis of hyperthermia","volume":"43","author":"Hildebrandt","year":"2002","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Helderman, R., Loke, D.R., Kok, H.P., Oei, A.L., Tanis, P.J., Franken, N., and Crezee, J. (2019). Variation in Clinical Application of Hyperthermic Intraperitoneal Chemotherapy: A Review. Cancers (Basel), 11.","DOI":"10.3390\/cancers11010078"},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Avenda\u00f1o, C., and Men\u00e9ndez, J.C. (2015). Chapter 6\u2013Anticancer drugs that interact with the DNA minor groove. Medicinal Chemistry of Anticancer Drugs, Elsevier. [2nd ed.].","DOI":"10.1016\/B978-0-444-62649-3.00006-5"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1002\/jso.21051","article-title":"Drugs, carrier solutions and temperature in hyperthermic intraperitoneal chemotherapy","volume":"98","author":"Kusamura","year":"2008","journal-title":"J. Surg. Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1007\/s00280-016-2976-z","article-title":"Platinum-based drugs: Past, present and future","volume":"77","author":"Dilruba","year":"2016","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.ejphar.2014.07.025","article-title":"Cisplatin in cancer therapy: Molecular mechanisms of action","volume":"740","author":"Dasari","year":"2014","journal-title":"Eur. J. Pharmacol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"285","DOI":"10.2174\/157489206777442287","article-title":"Recent developments in the field of anticancer platinum complexes","volume":"1","author":"Galanski","year":"2006","journal-title":"Recent Pat. Anticancer. Drug Discov."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1007\/BF00257742","article-title":"Early clinical studies with cis-diammine-1,1-cyclobutane dicarboxylate platinum II","volume":"9","author":"Calvert","year":"1982","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1124\/mol.58.5.920","article-title":"Oxaliplatin-induced damage of cellular DNA","volume":"58","author":"Woynarowski","year":"2000","journal-title":"Mol. Pharmacol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"8113","DOI":"10.1039\/c0dt00292e","article-title":"The status of platinum anticancer drugs in the clinic and in clinical trials","volume":"39","author":"Wheate","year":"2010","journal-title":"Dalton Trans."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Focaccetti, C., Bruno, A., Magnani, E., Bartolini, D., Principi, E., Dallaglio, K., Bucci, E.O., Finzi, G., Sessa, F., and Noonan, D.M. (2015). Effects of 5-fluorouracil on morphology, cell cycle, proliferation, apoptosis, autophagy and ROS production in endothelial cells and cardiomyocytes. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0115686"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1038\/nm.3967","article-title":"The consensus molecular subtypes of colorectal cancer","volume":"21","author":"Guinney","year":"2015","journal-title":"Nat. Med."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"e204","DOI":"10.1002\/bjs.10788","article-title":"Histopathological and molecular classification of colorectal cancer and corresponding peritoneal metastases","volume":"105","author":"Ubink","year":"2018","journal-title":"Br. J. Surg."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1038\/s41418-017-0011-5","article-title":"Consensus molecular subtypes of colorectal cancer are recapitulated in in vitro and in vivo models","volume":"25","author":"Linnekamp","year":"2018","journal-title":"Cell Death Differ."},{"key":"ref_25","first-page":"6304","article-title":"Participation of p53 protein in the cellular response to DNA damage","volume":"51","author":"Kastan","year":"1991","journal-title":"Cancer Res."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1038\/nprot.2006.238","article-title":"Analysis of apoptosis by propidium iodide staining and flow cytometry","volume":"1","author":"Riccardi","year":"2006","journal-title":"Nat. Protoc."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"5120","DOI":"10.1158\/0008-5472.CAN-15-0816","article-title":"Hyperthermia selectively targets human papillomavirus in cervical tumors via p53-dependent apoptosis","volume":"75","author":"Oei","year":"2015","journal-title":"Cancer Res."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Kotecha, N., Krutzik, P.O., and Irish, J.M. (2010). Web-based analysis and publication of flow cytometry experiments. Current Protocols in Cytometry, John Wiley and Sons Inc.. Chapter 10, Unit 10\u201317.","DOI":"10.1002\/0471142956.cy1017s53"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.1038\/nprot.2006.339","article-title":"Clonogenic assay of cells in vitro","volume":"1","author":"Franken","year":"2006","journal-title":"Nat. Protoc."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1186\/1748-717X-6-64","article-title":"Comparison of RBE values of high-LET alpha-particles for the induction of DNA-DSBs, chromosome aberrations and cell reproductive death","volume":"6","author":"Franken","year":"2011","journal-title":"Radiat. Oncol."},{"key":"ref_31","first-page":"5379","article-title":"Hyperthermia exposure induces apoptosis and inhibits proliferation in HCT116 cells by upregulating miR-34a and causing transcriptional activation of p53","volume":"14","author":"Luo","year":"2017","journal-title":"Exp. Ther. Med."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1148\/123.2.463","article-title":"Cellular responses to combinations of hyperthermia and radiation","volume":"123","author":"Dewey","year":"1977","journal-title":"Radiology"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"109","DOI":"10.4251\/wjgo.v2.i2.109","article-title":"A pharmacological review on intraperitoneal chemotherapy for peritoneal malignancy","volume":"2","author":"Yan","year":"2010","journal-title":"World J. Gastrointest. Oncol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1007\/s10585-019-09991-0","article-title":"Intraperitoneal mitomycin C improves survival compared to cytoreductive surgery alone in an experimental model of high-grade pseudomyxoma peritonei","volume":"36","author":"Sorensen","year":"2019","journal-title":"Clin. Exp. Metastasis"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1016\/j.eururo.2004.06.009","article-title":"The effect of hyperthermia on mitomycin-C induced cytotoxicity in four human bladder cancer cell lines","volume":"46","author":"Jansen","year":"2004","journal-title":"Eur. Urol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/S0378-4347(97)00291-0","article-title":"Sensitive and convenient high-performance liquid chromatographic method for the determination of mitomycin C in human plasma","volume":"698","author":"Joseph","year":"1997","journal-title":"J. Chromatogr. B Biomed. Sci. Appl."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/S0378-4347(00)82641-9","article-title":"High-performance liquid chromatographic determination of mitomycin C in rat and human plasma and urine","volume":"495","author":"Dalton","year":"1989","journal-title":"J. Chromatogr."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/S0378-4347(00)84429-1","article-title":"Liquid chromatographic determination of mitomycin C in human plasma and urine","volume":"274","author":"Eksborg","year":"1983","journal-title":"J. Chromatogr."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1002\/bjs.11206","article-title":"Organoids from colorectal peritoneal metastases as a platform for improving hyperthermic intraperitoneal chemotherapy","volume":"106","author":"Ubink","year":"2019","journal-title":"Br. J. Surg."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1002\/jso.23722","article-title":"The American Society of Peritoneal Surface Malignancies evaluation of HIPEC with Mitomycin C versus Oxaliplatin in 539 patients with colon cancer undergoing a complete cytoreductive surgery","volume":"110","author":"Esquivel","year":"2014","journal-title":"J. Surg. Oncol."},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Reinacher-Schick, A., Schulmann, K., Modest, D.P., Bruns, N., Graeven, U., Jaworska, M., Greil, R., Porschen, R., Arnold, D., and Schmiegel, W. (2012). Effect of KRAS codon13 mutations in patients with advanced colorectal cancer (advanced CRC) under oxaliplatin containing chemotherapy. Results from a translational study of the AIO colorectal study group. BMC Cancer, 12.","DOI":"10.1186\/1471-2407-12-349"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"LBA3503","DOI":"10.1200\/JCO.2018.36.18_suppl.LBA3503","article-title":"A UNICANCER phase III trial of hyperthermic intra-peritoneal chemotherapy (HIPEC) for colorectal peritoneal carcinomatosis (PC): PRODIGE 7","volume":"36","author":"Quenet","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/S2468-1253(19)30239-0","article-title":"Adjuvant hyperthermic intraperitoneal chemotherapy in patients with locally advanced colon cancer (COLOPEC): A multicentre, open-label, randomised trial","volume":"4","author":"Klaver","year":"2019","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.ejso.2018.10.542","article-title":"HIPEC with oxaliplatin for colorectal peritoneal metastasis: The end of the road?","volume":"45","author":"Ceelen","year":"2019","journal-title":"Eur. J. Surg. Oncol."},{"key":"ref_45","first-page":"1","article-title":"Colorectale peritoneale metastasen: Is er nog plaats voor chirurgie en HIPEC?","volume":"13","author":"Ceelen","year":"2019","journal-title":"Onco Hemato"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/s002800050955","article-title":"Supraadditive effect of 2\u2032,2\u2032-difluorodeoxycytidine (gemcitabine) in combination with oxaliplatin in human cancer cell lines","volume":"44","author":"Faivre","year":"1999","journal-title":"Cancer Chemoth. Pharmacol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1080\/02841860500247552","article-title":"In vitro radiosensitization by oxaliplatin and 5-fluorouracil in a human colon cancer cell line","volume":"44","author":"Johnsson","year":"2005","journal-title":"Acta Oncol."},{"key":"ref_48","first-page":"3259","article-title":"Oxaliplatin exerts potent in vitro cytotoxicity in colorectal and pancreatic cancer cell lines and liver metastases","volume":"20","author":"Kornmann","year":"2000","journal-title":"Anticancer Res."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1002\/jso.23546","article-title":"The use of Oxaliplatin or Mitomycin C in HIPEC treatment for peritoneal carcinomatosis from colorectal cancer: A comparative study","volume":"109","author":"Hompes","year":"2014","journal-title":"J. Surg. Oncol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.critrevonc.2019.06.014","article-title":"Systematic review of published literature on oxaliplatin and mitomycin C as chemotherapeutic agents for hyperthermic intraperitoneal chemotherapy in patients with peritoneal metastases from colorectal cancer","volume":"142","author":"Wisselink","year":"2019","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_51","first-page":"45","article-title":"Chemotherapy for intraperitoneal use: A review of hyperthermic intraperitoneal chemotherapy and early post-operative intraperitoneal chemotherapy","volume":"7","author":"Goodman","year":"2016","journal-title":"J. Gastrointest. Oncol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1159\/000011847","article-title":"Heated intraoperative intraperitoneal mitomycin C and early postoperative intraperitoneal 5-fluorouracil: Pharmacokinetic studies","volume":"55","author":"Jacquet","year":"1998","journal-title":"Oncology"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1002\/jso.24906","article-title":"5-fluorouracil combined with cisplatin and mitomycin C as an optimized regimen for hyperthermic intraperitoneal chemotherapy in gastric cancer","volume":"117","author":"Murata","year":"2018","journal-title":"J. Surg. Oncol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"399","DOI":"10.3892\/mco.2014.244","article-title":"Hyperthermic intraperitoneal chemotherapy with mitomycin C and 5-fluorouracil in patients at high risk of peritoneal metastasis from colorectal cancer: A preliminary clinical study","volume":"2","author":"Shimizu","year":"2014","journal-title":"Mol. Clin. Oncol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"44593","DOI":"10.18632\/oncotarget.17861","article-title":"The effect of thermal dose on hyperthermia-mediated inhibition of DNA repair through homologous recombination","volume":"8","author":"Laffeber","year":"2017","journal-title":"Oncotarget"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"9851","DOI":"10.1073\/pnas.1101053108","article-title":"Mild hyperthermia inhibits homologous recombination, induces BRCA2 degradation, and sensitizes cancer cells to poly (ADP-ribose) polymerase-1 inhibition","volume":"108","author":"Krawczyk","year":"2011","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1080\/02656730210123534","article-title":"Thermal enhancement of melphalan and oxaliplatin cytotoxicity in vitro","volume":"18","author":"Urano","year":"2002","journal-title":"Int. J. Hyperth."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1007\/s004320050315","article-title":"Inactivation of p53 and of pRb protects human colorectal carcinoma cells against hyperthermia-induced cytotoxicity and apoptosis","volume":"125","author":"Ceha","year":"1999","journal-title":"J. Cancer. Res. Clin. Oncol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1080\/02656730117221","article-title":"Wild-type p53-function is not required for hyperthermia-enhanced cytotoxicity of cisplatin","volume":"17","author":"Franken","year":"2001","journal-title":"Int. J. Hyperth."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.jinorgbio.2017.04.022","article-title":"Copper transporter 1 in human colorectal cancer cell lines: Effects of endogenous and modified expression on oxaliplatin cytotoxicity","volume":"177","author":"Cui","year":"2017","journal-title":"J. Inorg. Biochem."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1039\/C7MT00334J","article-title":"Relevance of copper transporter 1 and organic cation transporters 1-3 for oxaliplatin uptake and drug resistance in colorectal cancer cells","volume":"10","author":"Buss","year":"2018","journal-title":"Metallomics"}],"container-title":["Cells"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2073-4409\/9\/8\/1775\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T09:51:39Z","timestamp":1760176299000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2073-4409\/9\/8\/1775"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,25]]},"references-count":61,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2020,8]]}},"alternative-id":["cells9081775"],"URL":"https:\/\/doi.org\/10.3390\/cells9081775","relation":{},"ISSN":["2073-4409"],"issn-type":[{"value":"2073-4409","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,25]]}}}